Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

The clinical spectrum of hydrocephalus in adults: report of the first 517 patients of the Adult Hydrocephalus Clinical Research Network registry.

Williams MA, Nagel SJ, Luciano MG, Relkin N, Zwimpfer TJ, Katzen H, Holubkov R, Moghekar A, Wisoff JH, McKhann GM, Golomb J, Edwards RJ, Hamilton MG.

J Neurosurg. 2019 May 24:1-12. doi: 10.3171/2019.2.JNS183538. [Epub ahead of print]

PMID:
31125971
2.

Abstracts from Hydrocephalus 2016.

Adam A, Robison J, Lu J, Jose R, Badran N, Vivas-Buitrago T, Rigamonti D, Sattar A, Omoush O, Hammad M, Dawood M, Maghaslah M, Belcher T, Carson K, Hoffberger J, Jusué Torres I, Foley S, Yasar S, Thai QA, Wemmer J, Klinge P, Al-Mutawa L, Al-Ghamdi H, Carson KA, Asgari M, de Zélicourt D, Kurtcuoglu V, Garnotel S, Salmon S, Balédent O, Lokossou A, Page G, Balardy L, Czosnyka Z, Payoux P, Schmidt EA, Zitoun M, Sevestre MA, Alperin N, Baudracco I, Craven C, Matloob S, Thompson S, Haylock Vize P, Thorne L, Watkins LD, Toma AK, Bechter K, Pong AC, Jugé L, Bilston LE, Cheng S, Bradley W, Hakim F, Ramón JF, Cárdenas MF, Davidson JS, García C, González D, Bermúdez S, Useche N, Mejía JA, Mayorga P, Cruz F, Martinez C, Matiz MC, Vallejo M, Ghotme K, Soto HA, Riveros D, Buitrago A, Mora M, Murcia L, Bermudez S, Cohen D, Dasgupta D, Curtis C, Domínguez L, Remolina AJ, Grijalba MA, Whitehouse KJ, Edwards RJ, Eleftheriou A, Lundin F, Fountas KN, Kapsalaki EZ, Smisson HF, Robinson JS, Fritsch MJ, Arouk W, Garzon M, Kang M, Sandhu K, Baghawatti D, Aquilina K, James G, Thompson D, Gehlen M, Schmid Daners M, Eklund A, Malm J, Gomez D, Guerra M, Jara M, Flores M, Vío K, Moreno I, Rodríguez S, Ortega E, Rodríguez EM, McAllister JP, Guerra MM, Morales DM, Sival D, Jimenez A, Limbrick DD, Ishikawa M, Yamada S, Yamamoto K, Junkkari A, Häyrinen A, Rauramaa T, Sintonen H, Nerg O, Koivisto AM, Roine RP, Viinamäki H, Soininen H, Luikku A, Jääskeläinen JE, Leinonen V, Kehler U, Lilja-Lund O, Kockum K, Larsson EM, Riklund K, Söderström L, Hellström P, Laurell K, Kojoukhova M, Sutela A, Vanninen R, Vanha KI, Timonen M, Rummukainen J, Korhonen V, Helisalmi S, Solje E, Remes AM, Huovinen J, Paananen J, Hiltunen M, Kurki M, Martin B, Loth F, Luciano M, Luikku AJ, Hall A, Herukka SK, Mattila J, Lötjönen J, Alafuzoff I, Jurjević I, Miyajima M, Nakajima M, Murai H, Shin T, Kawaguchi D, Akiba C, Ogino I, Karagiozov K, Arai H, Reis RC, Teixeira MJ, Valêncio CG, da Vigua D, Almeida-Lopes L, Mancini MW, Pinto FCG, Maykot RH, Calia G, Tornai J, Silvestre SSS, Mendes G, Sousa V, Bezerra B, Dutra P, Modesto P, Oliveira MF, Petitto CE, Pulhorn H, Chandran A, McMahon C, Rao AS, Jumaly M, Solomon D, Moghekar A, Relkin N, Hamilton M, Katzen H, Williams M, Bach T, Zuspan S, Holubkov R, Rigamonti A, Clemens G, Sharkey P, Sanyal A, Sankey E, Rigamonti K, Naqvi S, Hung A, Schmidt E, Ory-Magne F, Gantet P, Guenego A, Januel AC, Tall P, Fabre N, Mahieu L, Cognard C, Gray L, Buttner-Ennever JA, Takagi K, Onouchi K, Thompson SD, Thorne LD, Tully HM, Wenger TL, Kukull WA, Doherty D, Dobyns WB, Moran D, Vakili S, Patel MA, Elder B, Goodwin CR, Crawford JA, Pletnikov MV, Xu J, Blitz A, Herzka DA, Guerrero-Cazares H, Quiñones-Hinojosa A, Mori S, Saavedra P, Treviño H, Maitani K, Ziai WC, Eslami V, Nekoovaght-Tak S, Dlugash R, Yenokyan G, McBee N, Hanley DF.

Fluids Barriers CNS. 2017 Jun 7;14(Suppl 1):15. doi: 10.1186/s12987-017-0054-5. No abstract available.

3.

Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis.

Chen Z, Liu C, Zhang J, Relkin N, Xing Y, Li Y.

Fluids Barriers CNS. 2017 May 10;14(1):13. doi: 10.1186/s12987-017-0062-5. Review.

4.

A phase 3 trial of IV immunoglobulin for Alzheimer disease.

Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2017 May 2;88(18):1768-1775. doi: 10.1212/WNL.0000000000003904. Epub 2017 Apr 5.

5.

Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study.

Correa DD, Root JC, Kryza-Lacombe M, Mehta M, Karimi S, Hensley ML, Relkin N.

Brain Imaging Behav. 2017 Dec;11(6):1652-1663. doi: 10.1007/s11682-016-9608-4.

6.

Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes.

Knight EM, Kim SH, Kottwitz JC, Hatami A, Albay R, Suzuki A, Lublin A, Alberini CM, Klein WL, Szabo P, Relkin NR, Ehrlich M, Glabe CG, Gandy S, Steele JW.

Neurol Neuroimmunol Neuroinflamm. 2016 May 10;3(3):e237. doi: 10.1212/NXI.0000000000000237. eCollection 2016 Jun.

7.

Structural connectome disruption at baseline predicts 6-months post-stroke outcome.

Kuceyeski A, Navi BB, Kamel H, Raj A, Relkin N, Toglia J, Iadecola C, O'Dell M.

Hum Brain Mapp. 2016 Jul;37(7):2587-601. doi: 10.1002/hbm.23198. Epub 2016 Mar 26.

8.

Two Novel Psychomotor Tasks in Idiopathic Normal Pressure Hydrocephalus.

Rossetti MA, Piryatinsky I, Ahmed FS, Klinge PM, Relkin NR, Salloway S, Ravdin LD, Brenner E, Malloy PF, Levin BE, Broggi M, Gavett R, Maniscalco JS, Katzen H.

J Int Neuropsychol Soc. 2016 Mar;22(3):341-9. doi: 10.1017/S1355617715001125. Epub 2016 Jan 28.

PMID:
26817685
9.

Prospective assessment of white matter integrity in adult stem cell transplant recipients.

Correa DD, Wang Y, West JD, Peck KK, Root JC, Baser RE, Thaler HT, Shore TB, Jakubowski A, Saykin AJ, Relkin N.

Brain Imaging Behav. 2016 Jun;10(2):486-96. doi: 10.1007/s11682-015-9423-3.

10.

An update on research priorities in hydrocephalus: overview of the third National Institutes of Health-sponsored symposium "Opportunities for Hydrocephalus Research: Pathways to Better Outcomes".

McAllister JP 2nd, Williams MA, Walker ML, Kestle JR, Relkin NR, Anderson AM, Gross PH, Browd SR; Hydrocephalus Symposium Expert Panel.

J Neurosurg. 2015 Dec;123(6):1427-38. doi: 10.3171/2014.12.JNS132352. Epub 2015 Jun 19.

PMID:
26090833
11.

MRI assessment of the effects of acetazolamide and external lumbar drainage in idiopathic normal pressure hydrocephalus.

Ivkovic M, Reiss-Zimmermann M, Katzen H, Preuss M, Kovanlikaya I, Heier L, Alperin N, Hoffmann KT, Relkin N.

Fluids Barriers CNS. 2015 Apr 2;12:9. doi: 10.1186/s12987-015-0004-z.

12.

Exploring the brain's structural connectome: A quantitative stroke lesion-dysfunction mapping study.

Kuceyeski A, Navi BB, Kamel H, Relkin N, Villanueva M, Raj A, Toglia J, O'Dell M, Iadecola C.

Hum Brain Mapp. 2015 Jun;36(6):2147-60. doi: 10.1002/hbm.22761. Epub 2015 Feb 5.

13.

Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimer's Disease.

Raj A, LoCastro E, Kuceyeski A, Tosun D, Relkin N, Weiner M; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Cell Rep. 2015 Jan 20;10(3):359-369. doi: 10.1016/j.celrep.2014.12.034. Epub 2015 Jan 15.

14.

Intravenous immunoglobulin for Alzheimer's disease.

Relkin N.

Clin Exp Immunol. 2014 Dec;178 Suppl 1:27-9. doi: 10.1111/cei.12500. No abstract available.

15.

Author response.

Alperin N, Olio C, Relkin N.

Neurology. 2014 Nov 4;83(19):1774. No abstract available.

PMID:
25538969
16.

A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.

Green RC, Christensen KD, Cupples LA, Relkin NR, Whitehouse PJ, Royal CD, Obisesan TO, Cook-Deegan R, Linnenbringer E, Butson MB, Fasaye GA, Levinson E, Roberts JS; REVEAL Study Group.

Alzheimers Dement. 2015 Oct;11(10):1222-30. doi: 10.1016/j.jalz.2014.10.014. Epub 2014 Dec 9.

17.

Low-dose acetazolamide reverses periventricular white matter hyperintensities in iNPH.

Gilbert GJ, Alperin N, Olio C, Relkin N.

Neurology. 2014 Nov 4;83(19):1773. doi: 10.1212/WNL.0000000000000994. No abstract available.

PMID:
25367060
18.

Intravenous immunoglobulins for Alzheimer's disease.

Puli L, Tanila H, Relkin N.

Curr Alzheimer Res. 2014;11(7):626-36. Review.

PMID:
25115546
19.

Clinical trials of intravenous immunoglobulin for Alzheimer's disease.

Relkin N.

J Clin Immunol. 2014 Jul;34 Suppl 1:S74-9. doi: 10.1007/s10875-014-0041-4. Epub 2014 Apr 24. Review.

PMID:
24760112
20.

Longitudinal effects of intravenous immunoglobulin on Alzheimer's cerebrospinal fluid proteome.

Shayan G, Adamiak B, Choe LH, Relkin N, Lee KH.

Electrophoresis. 2014 Jul;35(12-13):1821-7. doi: 10.1002/elps.201300609.

21.

Low-dose acetazolamide reverses periventricular white matter hyperintensities in iNPH.

Alperin N, Oliu CJ, Bagci AM, Lee SH, Kovanlikaya I, Adams D, Katzen H, Ivkovic M, Heier L, Relkin N.

Neurology. 2014 Apr 15;82(15):1347-51. doi: 10.1212/WNL.0000000000000313. Epub 2014 Mar 14.

22.

Amyloid-ß-directed immunotherapy for Alzheimer's disease.

Lannfelt L, Relkin NR, Siemers ER.

J Intern Med. 2014 Mar;275(3):284-95. doi: 10.1111/joim.12168. Review. Erratum in: J Intern Med. 2014 May;275(5):546.

23.

Diagnosis and management of idiopathic normal-pressure hydrocephalus.

Williams MA, Relkin NR.

Neurol Clin Pract. 2013 Oct;3(5):375-385.

24.
25.

Influence of comorbidities in idiopathic normal pressure hydrocephalus - research and clinical care. A report of the ISHCSF task force on comorbidities in INPH.

Malm J, Graff-Radford NR, Ishikawa M, Kristensen B, Leinonen V, Mori E, Owler BK, Tullberg M, Williams MA, Relkin NR.

Fluids Barriers CNS. 2013 Jun 10;10(1):22. doi: 10.1186/2045-8118-10-22.

26.

A prospective evaluation of changes in brain structure and cognitive functions in adult stem cell transplant recipients.

Correa DD, Root JC, Baser R, Moore D, Peck KK, Lis E, Shore TB, Thaler HT, Jakubowski A, Relkin N.

Brain Imaging Behav. 2013 Dec;7(4):478-90. doi: 10.1007/s11682-013-9221-8.

27.

Differential diagnosis of normal pressure hydrocephalus by MRI mean diffusivity histogram analysis.

Ivkovic M, Liu B, Ahmed F, Moore D, Huang C, Raj A, Kovanlikaya I, Heier L, Relkin N.

AJNR Am J Neuroradiol. 2013 Jun-Jul;34(6):1168-74. doi: 10.3174/ajnr.A3368. Epub 2012 Dec 20.

28.

Alzheimer's disease and Down's syndrome: treating two paths to dementia.

Weksler ME, Szabo P, Relkin NR, Reidenberg MM, Weksler BB, Coppus AM.

Autoimmun Rev. 2013 Apr;12(6):670-3. doi: 10.1016/j.autrev.2012.10.013. Epub 2012 Nov 29. Review.

PMID:
23201920
29.

Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model.

Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Fraser P, Westaway D, St George-Hyslop PH, Szabo P, Relkin NR, Buxbaum JD, Glabe CG, Protter AA, Martins RN, Ehrlich ME, Petsko GA, Yue Z, Gandy S.

Mol Psychiatry. 2013 Aug;18(8):889-97. doi: 10.1038/mp.2012.106. Epub 2012 Jul 31.

30.

Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapy.

Shayan G, Adamiak B, Relkin NR, Lee KH.

Electrophoresis. 2012 Jul;33(13):1975-9. doi: 10.1002/elps.201100660.

31.

A pilot study of quantitative MRI measurements of ventricular volume and cortical atrophy for the differential diagnosis of normal pressure hydrocephalus.

Moore DW, Kovanlikaya I, Heier LA, Raj A, Huang C, Chu KW, Relkin NR.

Neurol Res Int. 2012;2012:718150. doi: 10.1155/2012/718150. Epub 2011 Aug 7.

32.

Postshunt cognitive and functional improvement in idiopathic normal pressure hydrocephalus.

Katzen H, Ravdin LD, Assuras S, Heros R, Kaplitt M, Schwartz TH, Fink M, Levin BE, Relkin NR.

Neurosurgery. 2011 Feb;68(2):416-9. doi: 10.1227/NEU.0b013e3181ff9d01.

33.

Measurement of anti-beta amyloid antibodies in human blood.

Szabo P, Mujalli DM, Rotondi ML, Sharma R, Weber A, Schwarz HP, Weksler ME, Relkin N.

J Neuroimmunol. 2010 Oct 8;227(1-2):167-74. doi: 10.1016/j.jneuroim.2010.06.010. Epub 2010 Jul 31.

PMID:
20638733
34.

Clinical applications of intravenous immunoglobulins in neurology.

Hughes RA, Dalakas MC, Cornblath DR, Latov N, Weksler ME, Relkin N.

Clin Exp Immunol. 2009 Dec;158 Suppl 1:34-42. doi: 10.1111/j.1365-2249.2009.04025.x. Review.

35.

Upper extremity motor measures of Tap Test response in Normal Pressure Hydrocephalus.

Tsakanikas D, Katzen H, Ravdin LD, Relkin NR.

Clin Neurol Neurosurg. 2009 Nov;111(9):752-7. doi: 10.1016/j.clineuro.2009.07.017. Epub 2009 Aug 31.

PMID:
19720451
36.

Disclosure of APOE genotype for risk of Alzheimer's disease.

Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M, Sadovnick AD, Quaid KA, Chen C, Cook-Deegan R, Farrer LA; REVEAL Study Group.

N Engl J Med. 2009 Jul 16;361(3):245-54. doi: 10.1056/NEJMoa0809578.

37.

Current state of immunotherapy for Alzheimer's disease.

Relkin NR.

CNS Spectr. 2008 Oct;13(10 Suppl 16):39-41. Review. No abstract available.

PMID:
18955962
38.

Testing the mettle of PBT2 for Alzheimer's disease.

Relkin NR.

Lancet Neurol. 2008 Sep;7(9):762-3. doi: 10.1016/S1474-4422(08)70168-6. Epub 2008 Jul 30. No abstract available.

PMID:
18672401
39.

Disease-modifying approaches to Alzheimer's disease: challenges and opportunities-Lessons from donepezil therapy.

Sabbagh MN, Richardson S, Relkin N.

Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S109-18. doi: 10.1016/j.jalz.2007.11.013. Review.

PMID:
18631986
40.

Cholinergic components of frontal lobe function and dysfunction.

Rabin LA, Tanapat P, Relkin N.

Handb Clin Neurol. 2008;88:1-30. doi: 10.1016/S0072-9752(07)88001-8. Review. No abstract available.

PMID:
18631684
41.

Natural human antibodies to amyloid beta peptide.

Szabo P, Relkin N, Weksler ME.

Autoimmun Rev. 2008 Jun;7(6):415-20. doi: 10.1016/j.autrev.2008.03.007. Epub 2008 Apr 10. Review.

PMID:
18558354
42.

Features of gait most responsive to tap test in normal pressure hydrocephalus.

Ravdin LD, Katzen HL, Jackson AE, Tsakanikas D, Assuras S, Relkin NR.

Clin Neurol Neurosurg. 2008 May;110(5):455-61. doi: 10.1016/j.clineuro.2008.02.003. Epub 2008 Mar 21.

43.

Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience.

Christensen KD, Roberts JS, Royal CD, Fasaye GA, Obisesan T, Cupples LA, Whitehouse PJ, Butson MB, Linnenbringer E, Relkin NR, Farrer L, Cook-Deegan R, Green RC.

Genet Med. 2008 Mar;10(3):207-14. doi: 10.1097/GIM.0b013e318164e4cf.

44.

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME.

Neurobiol Aging. 2009 Nov;30(11):1728-36. doi: 10.1016/j.neurobiolaging.2007.12.021. Epub 2008 Feb 21.

PMID:
18294736
45.

8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease.

Choe L, D'Ascenzo M, Relkin NR, Pappin D, Ross P, Williamson B, Guertin S, Pribil P, Lee KH.

Proteomics. 2007 Oct;7(20):3651-60.

46.
47.

Normal pressure hydrocephalus.

Tsakanikas D, Relkin N.

Semin Neurol. 2007 Feb;27(1):58-65. Review.

PMID:
17226742
48.

Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: the REVEAL Study.

Eckert SL, Katzen H, Roberts JS, Barber M, Ravdin LD, Relkin NR, Whitehouse PJ, Green RC.

Genet Med. 2006 Dec;8(12):746-51.

PMID:
17172937
49.

Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease.

Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH.

Ann Neurol. 2007 Feb;61(2):120-9.

PMID:
17167789
50.

Development and testing of a new outcome measure of relationship between patients with Alzheimer's disease and their partners.

Reilly MC, Relkin NR, Zbrozek AS.

Am J Alzheimers Dis Other Demen. 2006 Aug-Sep;21(4):249-57.

PMID:
16948289

Supplemental Content

Loading ...
Support Center